Sagent Pharmaceuticals Announces the Launch of Acetazolamide for Injection, USP
SCHAUMBURG, Ill., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Acetazolamide for Injection, USP, the generic form of the carbonic anhydrase inhibitor Diamox®, in a latex-free vial presentation. According to IMS data for the 12 months ending September 2012, the US market for Acetazolamide for Injection, USP approximated $9.5 million. As with all products in Sagent's portfolio, Acetazolamide features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
About Acetazolamide for Injection, USP
Acetazolamide for Injection, USP is indicated for adjunctive treatment of edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); and chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
The package insert, available at www.sagentpharma.com, contains the indications, complete side effect profile, and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605Source: Sagent Pharmaceuticals, Inc. 2012 GlobeNewswire, Inc.